Prosecution Insights
Last updated: November 12, 2026
Application No. 18/718,862

RECOMBINANT PROTEIN FOR SARS-COV2 DISEASE

Non-Final OA §102§112§DP
Filed
Jun 12, 2024
Priority
Dec 16, 2021 — IN 202121058651 +1 more
Examiner
REYNOLDS, FRED H
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNICHEM LABORATORIES LIMITED
OA Round
1 (Non-Final)
33%
Grant Probability
At Risk
1-2
OA Rounds
73%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
283 granted / 852 resolved
-26.8% vs TC avg
Strong +40% interview lift
Without
With
+39.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
97 currently pending
Career history
954
Total Applications
across all art units

Office Action

§102 §112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Examiner’s Note A written description rejection was considered for the variation of the sequence of claim 1 tied to the intended use as a functional requirement. However, Leonidas et al (J. Mol. Bio. (2007) 368 p1145-1161, cited in restriction/election requirement) describes a crystal structure of this protein binding to a glycan. This is considered sufficient to allow a person of skill in the art to know what areas of the molecule can be varied and maintain activity. Likewise, a scope of enablement rejection was considered for the various coronaviruses, as applicants have only examined a single SARS CoV2 spike protein. However, the international search report and the U.S. Patent documents cited by applicants describe reduction of inflammation and antiviral activity of these compounds, which would be useful for more than SARS CoV2. Finally, there appears to be a mistake in table 4 (p23 of specification). The level of cytokines in the positive control is listed as 0.0. It is not clear how this can be corrected without adding new matter, however. Election/Restrictions Applicant’s election without traverse of group I (polypeptides) and SEQ ID 2 in the reply filed on 3 Sept, 2026 is acknowledged. The requirement is deemed proper and is therefore made FINAL. Applicants have elected SEQ ID 2. A search was conducted for this invention, and a reference that anticipated it was found. As a result, claims 1-6, 8, and 9 were rejected, and claims 7, 10, and 11-14 were withdrawn from consideration. Claims Status Claims 1-14 are pending. Claim7, 10, and 11-14 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 3 Sept, 2026. Claim Objections Claims 1, 2, and 8 are objected to because of the following informalities: these claims require a specific level of homology to SEQ ID 1. Applicants have defined homology to be identical with identity (p7, 3d and 4th paragraphs), but this is not how the term is used in the art (Koonin et al, (2003) NCBI Bookshelf, 1st page, 3d and 4th paragraphs). Appropriate correction is required, possibly by amending to percent identity instead of percent homology. Specification The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code, note p7, 4th paragraph, for example. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-6, 8, and 9 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for treating coronavirus infections, does not reasonably provide enablement for preventing. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The MPEP states “There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is ‘undue.’ These factors include, but are not limited to: 1) the breadth of the claims; 2) the nature of the invention; 3) the state of the prior art; 4) the level of one of ordinary skill; 5) the level of predictability in the art; 6) the amount of direction provided by the inventor; 7) the existence of working examples; and 8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure” (MPEP 2164.01(a). 1 and 2) the breadth of the claims and the nature of the invention: Applicants are claiming a lectin protein and variants, with the intended use to prevent or treat coronavirus infections. While applicants may intend prophylactic use with the preventing language, that is not what is claimed. 3) the state of the prior art: Barre et al (Cells (2021) 10 1619, cited by applicants) discusses lectin binding to various coronaviruses (title) and how this feature can be used to treat coronavirus infections (abstract). 4) the level of one of ordinary skill: The level of skill in the art is high. 5) the level of predictability in the art: Biology is constantly confounding common sense and experience, leaving a relatively low level of predictability in the art. 6 and 7) the amount of direction provided by the inventor and the existence of working examples: Applicants demonstrate that the lectin will inhibit the interaction between a spike protein of SARS CoV2 and ACE2 (p19, 1st paragraph), and look at cytokine levels in culture medium from cells exposed to the protein, both with and without the inhibitor (p22-23). 8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure: All of applicant’s experiments are with cells treated with a spike protein, and the prior art discusses lectins interfering with binding of spike proteins. However, if there is no virus (i.e. preventing), there is no spike protein, and the treatment will have no effect. Thus, it will take undue experimentation to use the invention to prevent infections as claimed. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. first rejection Claims 1-6, 8, and 9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1, and claims dependent on it, has an intended use of prevention or treatment of a disease caused by a coronavirus “or a mutant thereof.” While this clearly allows for an intended use broader than treating coronaviruses, it is not clear how broad. Everything is a mutant of something else; this is how evolution works, but the invention clearly will not work for certain bacterial infections (or a mouse infestation, for that matter). Note that claims 8 and 9 use similar language. second rejection Claim 2 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 2 lists a number of different percent homologies that the protein must meet, but these are overlapping ranges. It is not clear which percent homology is the claim limitation. third rejection Claims 4 and 6 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 4 and 6 give limitations of the method of action based on binding to SARS CoV2 virus or proteins. However, the scope of the intended use is bounded by claim 1, from which these claims depend, and is broader than just SARS CoV2. It is not clear how this mismatch affects the claim scope. fourth rejection Claim 5 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 5 uses “such as” language describing the cytokines inhibited by the therapy. This makes it unclear if the language included in the following clause are limitations or examples. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-6, 8, and 9 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Swamy et al (WO 2010095143). Swamy et al discuss recombinant lectins for treating cancer (title), including SEQ ID 2 (fig 3), identical to SEQ ID 2 of the examined claims. Final purification is via size exclusion chromatography against TBS pH 7.2 (p9, 2nd paragraph), a pharmaceutically acceptable carrier. Swamy et al describe a polypeptide identical to that claimed by applicants. While applicants claim a utility of preventing or treating a coronavirus infection, under US patent law, an anticipatory reference need not disclose the utility of a product (MPEP 2122). Thus, this reference anticipates claims 1-3. While the reference is silent as to binding to spike proteins or cytokine production, it is the identical polypeptide, so will necessarily have the same properties – the discovery of a new property of a known compound does not render it patentably new to the discoverer (MPEP 2112(I)). Thus, the reference anticipates claims 4-6. Swamy et al discloses a pharmaceutically acceptable formulation with a carrier, anticipating claims 8 and 9. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. first rejection Claims 1-6, 8, and 9 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3, and 12 of copending Application No. 18/692,059 (US 20250302974) (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims anticipate the examined claims. Competing claim 1 describes a formulation comprising a lectin, while competing claim 3 describes a Markush group of lectins, including SEQ ID 2, identical with SEQ ID 2 of the examined claims. Competing claim 12 specifies a pharmaceutical formulation of the lectin of claim 1. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. second rejection Claims 1-6, 8, and 9 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4 of copending Application No. 18/828,436 (US 20250152668) (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims anticipate the examined claims. Competing claim 1 describes a method of treatment using SEQ ID 2, identical with SEQ ID 2 of the examined claims. Note a treatment requires a pharmaceutically acceptable formulation. Competing claim 4 specifies inhibition of cytokines. third rejection Claims 1-6, 8, and 9 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 5, and 8 of copending Application No. 18/684,064 (US 20250064890) (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims anticipate the examined claims. Competing claim 1 describes a genus of lectins, while competing claim 5 describes a subgenus Markush group, including SEQ ID 2 (identical with SEQ ID 2 of the examined claims). Competing claim 8 specifies a pharmaceutical formulation that can have a diluent. fourth rejection Claims 1, 2, 4-6, 8, and 9 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 14 of copending Application No. 18/691,412 (US 20240383950) (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims anticipate the examined claims. Competing claim 1 describes a sequence with identity to SEQ ID 1, differing from SEQ ID 1 of the examined claims by two mutations (out of 141 amino acids). Competing claim 14 describes a pharmaceutical formulation comprising an excipient. fifth rejection Claims 1-6, 8, and 9 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 9 of copending Application No. 18/260,404 (US 20240398899) (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims anticipate the examined claims. Competing claim 9 specifies a method of treatment, comprising a polypeptide selected from a Markush group of sequences, including SEQ ID 1 (identical with SEQ ID 2 of the examined claims). Note that a method of treatment requires administration, which requires a diluent. sixth rejection Claims 1, 2, 4-6, 8, and 9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 2 of U.S. Patent No. 11,965,003 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims anticipate the examined claims. Competing claim 1 describes a lectin that varies by 2 amino acids vs SEQ ID 1 of the examined claims, while competing claim 2 specifies the same lectin and a pharmaceutically acceptable diluent. seventh rejection Claims 1-6 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 2 of U.S. Patent No. 12,291,733 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims anticipate the examined claims. Competing claim 1 describes a method of producing a recombinant lectin selected from a genus that includes SEQ ID 1, identical with SEQ ID 2 of the examined claims. eighth rejection Claims 1-6, 8 and 9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 2 of U.S. Patent No. 12,291,733 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims anticipate the examined claims. Competing claim 1 describes a formulation comprising SEQ ID 1 (identical with SEQ ID 2 of the examined claims) and pharmaceutically acceptable excipients. ninth rejection Claims 1-6, 8 and 9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 2 of U.S. Patent No. 12,714,737 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the competing claims anticipate the examined claims. Competing claim 1 describes a formulation comprising SEQ ID 1 (identical with SEQ ID 2 of the examined claims) and pharmaceutically acceptable excipients. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to FRED REYNOLDS whose telephone number is (571)270-7214. The examiner can normally be reached M-Th 9-3:30. Examiner interviews are available via telephone and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /FRED H REYNOLDS/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Jun 12, 2024
Application Filed
Sep 23, 2026
Non-Final Rejection mailed — §102, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790604
CAPSULE PROTEIN AND MULTIMERIC COMPLEX COMPOSITION THEREOF, AND PHARMACEUTICAL COMPOSITION USING SAME
4y 6m to grant Granted Nov 10, 2026
Patent 12766182
TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF
2y 7m to grant Granted Oct 20, 2026
Patent 12760079
CNP Variants and Conjugates Thereof
4y 7m to grant Granted Oct 13, 2026
Patent 12753208
ANTIVIRAL STRUCTURALLY-STABILIZED EBOLAVIRUS PEPTIDES AND USES THEREOF
3y 5m to grant Granted Oct 06, 2026
Patent 12753222
POLYMERIC FORMS OF H-NOX PROTEINS
2y 5m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
33%
Grant Probability
73%
With Interview (+39.7%)
Low
PTA Risk
Based on 852 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month